BION BB Biotech AG

SWX · CH · Healthcare · Biotechnology · bbbiotech.ch

49.55CHF-1.49%Mkt Cap: 3.12B $P/E: 2.02Today

BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medica…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap3.12B USD

Enterprise Value-344.95M USD

Revenue (TTM)1.21B USD

Gross Profit1.21B USD

Net Income (TTM)659.83M USD

Revenue/Share19.24 CHF

Last Price49.55 CHF

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees10

CountryCH

SectorHealthcare

IndustryBiotechnology

ISINCH0038389992

Valuation

P/E (Trailing)2.02

P/E (Forward)-76.47

PEG—

EV/EBITDA—

EV/Revenue-0.29

P/S2.62

P/B0.90

EPS (TTM)24.55

EPS (Forward)-0.66

52W Range

36.3064% of range56.90

52W High56.90 CHF

52W Low36.30 CHF

Profitability

Gross Margin100.00%

Oper. Margin97.74%

EBITDA Margin0.00%

Profit Margin98.49%

ROE20.81%

ROA20.75%

Growth

Revenue Growth116257.70%

Earnings Growth—

Cash Flow & Leverage

Operating CF345.57M USD

CapEx (TTM)—

FCF Margin233.15%

FCF Yield90.41%

Net Debt-3.51B USD

Net Debt/EBITDA—

Balance Sheet

Debt/Equity—

Current Ratio583.97

Quick Ratio583.91

Book Value/Sh55.93 CHF

Cash/Share55.78 CHF

Dividends

Fwd Div Rate2.25 CHF

Trail. Div Rate2.25 CHF

Div. Yield4.47%

5Y Avg Yield5.49%

Payout Ratio9.17%

Ex-Div DateMar 23, 2026

Pay DateMar 25, 2025

Splits

Last Split5:1

Split DateMar 29, 2016

Analyst Consensus

Rating1.5 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)69.00 CHF

Upside (mean)+39.3%

Target Range65.00 CHF – 73.00 CHF

65.00+39.3% to mean73.00

# Analysts2

Ownership

Shares Out.55.15M

Float—

Insiders0.08%

Institutions19.91%

Technical

SMA 5053.17 (-6.8%)

SMA 20047.79 (+3.7%)

Beta0.67

S&P 52W Chg14.58%

Avg Vol (30d)77.40K

Avg Vol (10d)63.64K

Technical Indicators

RSI (14)34.2

MACD-0.7030

MACD Signal-0.5375

MACD Hist.-0.1655

BB Upper54.10 CHF

BB Middle52.05 CHF

BB Lower50.01 CHF

BB Width7.85%

ATR (14)0.9868 CHF

Vol Ratio (20d)1.24x